JP2014515407A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515407A5
JP2014515407A5 JP2014513785A JP2014513785A JP2014515407A5 JP 2014515407 A5 JP2014515407 A5 JP 2014515407A5 JP 2014513785 A JP2014513785 A JP 2014513785A JP 2014513785 A JP2014513785 A JP 2014513785A JP 2014515407 A5 JP2014515407 A5 JP 2014515407A5
Authority
JP
Japan
Prior art keywords
group
bonds
pharmaceutical formulation
divalent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014513785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515407A (ja
JP6448366B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/040711 external-priority patent/WO2012167236A1/en
Publication of JP2014515407A publication Critical patent/JP2014515407A/ja
Publication of JP2014515407A5 publication Critical patent/JP2014515407A5/ja
Application granted granted Critical
Publication of JP6448366B2 publication Critical patent/JP6448366B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014513785A 2011-06-03 2012-06-04 ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用 Active JP6448366B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492940P 2011-06-03 2011-06-03
US61/492,940 2011-06-03
PCT/US2012/040711 WO2012167236A1 (en) 2011-06-03 2012-06-04 Oral formulations of mitochondrially-targeted antioxidants and their preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017196849A Division JP6461276B2 (ja) 2011-06-03 2017-10-10 ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用

Publications (3)

Publication Number Publication Date
JP2014515407A JP2014515407A (ja) 2014-06-30
JP2014515407A5 true JP2014515407A5 (enExample) 2015-07-02
JP6448366B2 JP6448366B2 (ja) 2019-01-09

Family

ID=47259946

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014513785A Active JP6448366B2 (ja) 2011-06-03 2012-06-04 ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用
JP2017196849A Active JP6461276B2 (ja) 2011-06-03 2017-10-10 ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017196849A Active JP6461276B2 (ja) 2011-06-03 2017-10-10 ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用

Country Status (10)

Country Link
US (2) US9192676B2 (enExample)
EP (1) EP2714024B1 (enExample)
JP (2) JP6448366B2 (enExample)
CN (1) CN103764132B (enExample)
AU (1) AU2012261854B2 (enExample)
BR (1) BR112013030605A2 (enExample)
CA (1) CA2837437C (enExample)
EA (1) EA031399B1 (enExample)
ES (1) ES2704064T3 (enExample)
WO (1) WO2012167236A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167236A1 (en) * 2011-06-03 2012-12-06 Mitotech Sa Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
WO2014116591A2 (en) * 2013-01-22 2014-07-31 Mitotech Sa Pharmaceutical formulations containing mitochondrially-targeted antioxidants
WO2015063553A2 (en) * 2013-04-11 2015-05-07 Mitotech S.A. Mitochondrially-targeted timoquinones and toluquinones
EP3116470B1 (en) 2014-02-25 2019-05-08 Mitotech SA Cosmetic compositions of mitochondrially targeted antioxidants
WO2019139831A1 (en) * 2018-01-10 2019-07-18 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate
US20230038070A1 (en) * 2019-12-10 2023-02-09 Mitotech S.A. Polymer matrixes for different compositions of mitochondrially targeted antioxidants
EP4125867A1 (en) * 2020-04-03 2023-02-08 Mitotech S.A. Use of mitochondria-targeted antioxidants to treat severe inflammatory conditions
CN114344274A (zh) * 2022-01-05 2022-04-15 盖茨汉普(武汉)植物应用研究有限公司 一种Mitoq抗氧化硬胶囊配方及制备工艺
WO2025078880A1 (en) * 2023-10-11 2025-04-17 Mitotech S.A. Mitochondria-targeted antioxidants for use in the treatment of cell balloooning-associated diseases, such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538974A (en) 1994-01-27 1996-07-23 Senju Pharamceutical Co., Ltd. Ophthalmic composition for lowering intraocular pressure
WO1999026582A2 (en) 1997-11-25 1999-06-03 University Of Otago Mitochondrially targeted compounds
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
US20070270381A1 (en) 2000-05-25 2007-11-22 Antipodean Pharmaceuticals, Inc. Mitochondrially targeted antioxidants
US20020044913A1 (en) 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
US6984636B2 (en) 2002-08-12 2006-01-10 Medical Research Council Mitochondrially targeted antioxidants
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
WO2006005759A2 (en) 2004-07-13 2006-01-19 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
US20070259908A1 (en) 2004-08-30 2007-11-08 Kaneka Corporation Mitochondria Activators
RU2318500C2 (ru) 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
EP2119436A4 (en) 2006-10-20 2010-03-03 Ltd Liability Company Mitotech PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF EYE DISEASES
EP2095713A1 (en) 2006-10-20 2009-09-02 Limited Liability Company "Mitotechnology" Composition for regenerating and stimulating growth of plants and for adapting plants to different stress factors
EA200901061A1 (ru) * 2007-01-29 2009-12-30 Общество С Ограниченной Ответственностью "Митотехнология" Фармацевтические и косметические композиции для ускорения процесса заживления ран и других поверхностных повреждений
WO2008127138A1 (fr) * 2007-04-11 2008-10-23 Limited Liability Company 'mitotechnology' Composition visant à ralentir le vieillissement et à allonger la durée de vie de l'organisme et utilisation de cette composition
US8518915B2 (en) * 2007-06-29 2013-08-27 Mitotech Sa Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
WO2009158348A1 (en) 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
MX2011011310A (es) 2009-04-28 2011-11-18 Edison Pharmaceuticals Inc Formulacion de tocotrienol quinonas para el tratamiento de enfermedades oftalmicas.
CN102548548B (zh) * 2009-06-10 2017-09-01 米拓科技有限公司(卢森堡) 用于医学和兽医学的眼科药物组合物
CN102791670A (zh) * 2009-11-13 2012-11-21 米拓科技有限责任公司 基于定向于线粒体的抗氧化剂的药物物质
WO2012167236A1 (en) * 2011-06-03 2012-12-06 Mitotech Sa Oral formulations of mitochondrially-targeted antioxidants and their preparation and use

Similar Documents

Publication Publication Date Title
US20220071929A1 (en) Application of r-ketamine and salt thereof as pharmaceuticals
ES2745471T3 (es) Formulaciones orales de liberación inmediata para quinazolinonas sustituidas
JP6462045B2 (ja) スルフォラファンの単離及び精製
JP2015530382A5 (enExample)
JP2009102342A5 (enExample)
JP2016534063A5 (enExample)
RU2013121788A (ru) Ингибиторы репликации вич
JP2013511496A5 (enExample)
JP2020517727A5 (enExample)
JP2013545730A5 (enExample)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
NZ703564A (en) Oral formulations and lipophilic salts of methylnaltrexone
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2016516772A (ja) オキサシクロヘプタン及びオキサビシクロヘプテンの配合物
JP2016516773A5 (enExample)
RU2016138795A (ru) Композиции на основе циклодекстрина и производного будесонида и способы их получения
JP5837919B2 (ja) (e)−4−カルボキシスチリル−4−クロロベンジルスルホンの改善された安定な水性製剤
CN104244936A (zh) 镇痛剂
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
RU2018130097A (ru) Лечение экземы кистей
JP2017516828A5 (enExample)
RU2012116226A (ru) Бронхолитическое средство на основе простагландина
KR20090040299A (ko) 특별히 표적화된 국소 투여를 위한 주사용 약제학적 조성물
JP2014530200A5 (enExample)
JP2009538822A (ja) 静脈におけるウイルスの治療